Mao N, Lee YSun, Salsabeel N, Zhang Z, Li D, Kaur H, Chen X, Chang Q, Mehta S, Barnes J et al..  2025.  Uncoupling of Akt and mTOR signaling drives resistance to Akt inhibition in PTEN loss prostate cancers.. Sci Adv. 11(6):eadq3802.

Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX et al..  2022.  Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.. N Engl J Med. 386(8):735-743.

Knauf JA, Luckett KA, Chen K-Y, Voza F, Socci ND, Ghossein R, Fagin JA.  2018.  Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.. J Clin Invest. 128(9):4086-4097.

Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TThi, Chaudhary N, Riely GJ, Li BT, Scott K et al..  2017.  An approach to suppress the evolution of resistance in BRAF-mutant cancer.. Nat Med. 23(8):929-937.

Reinartz R, Wang S, Kebir S, Silver DJ, Wieland A, Zheng T, Küpper M, Rauschenbach L, Fimmers R, Shepherd TM et al..  2017.  Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma.. Clin Cancer Res. 23(2):562-574.

Theodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, Bosenberg MW.  2017.  p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.. J Invest Dermatol. 137(10):2187-2196.

Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M et al..  2017.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.. Nature. 546(7658):431-435.

Röhrig F, Vorlová S, Hoffmann H, Wartenberg M, Escorcia FE, Keller S, Tenspolde M, Weigand I, Gätzner S, Manova K et al..  2017.  VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.. Oncogene. 36(1):1-12.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G et al..  2016.  DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.. Nat Med. 22(12):1488-1495.

Lin KH, Winter PS, Xie A, Roth C, Martz CA, Stein EM, Anderson GR, Tingley JP, Wood KC.  2016.  Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.. Sci Rep. 6:27696.

Dubrovsky L, Pankov D, Brea EJoseph, Dao T, Scott A, Yan S, O'Reilly RJ, Liu C, Scheinberg DA.  2014.  A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.. Blood. 123(21):3296-304.